Vergoeding 2019-2023 voor ATC-subgroep L04AG : Monoklonale antilichamen
- Raming voor de totale Zvw-populatie
| 2019 | 2020 | 2021 | 2022* | 2023* | |
|---|---|---|---|---|---|
| L04AG03 Natalizumab | 19.788.825 | 20.488.772 | 18.954.158 | 18.302.935 | 17.628.580 |
| L04AG04 Belimumab | 1.221.220 | 1.388.282 | 1.953.029 | 2.321.440 | 2.826.392 |
| L04AG05 Vedolizumab | 36.733.695 | 42.596.426 | 50.204.262 | 55.427.788 | 62.975.041 |
| L04AG06 Alemtuzumab | 2.948.563 | 1.165.468 | 1.414.602 | 1.397.014 | 1.140.460 |
| L04AG08 Ocrelizumab | 26.612.661 | 31.722.793 | 45.874.148 | 60.735.720 | 73.199.837 |
| L04AG11 Anifrolumab | . | . | . | 7.814 | 161.814 |
| Totaal | 87.304.964 | 97.361.742 | 118.400.199 | 138.192.710 | 157.932.124 |